Accolade price target raised to $18 from $14 at Canaccord

Canaccord analyst Richard Close raised the firm’s price target on Accolade to $18 from $14 and keeps a Buy rating on the shares. The analyst said with growth in all three areas advocacy, expert medical, and virtual care, all expected at ~20% or better, it’s hard not to like the outlook for Accolade. The march toward profitability is accelerating, and that bodes well for share price performance going forward.